|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk: OR (95% CI) = 0.84 (0.73-0.96) and 0.85 (0.62-1.15) for heterozygous and homozygote variant genotypes, respectively, compared with common homozygotes; p-trend = 0.01, false discovery rate = 0.14.
|
17311260 |
2007 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of MTR A2756G mutant allele and MTHFR C677T mutant allele in carriers was associated with increased breast cancer risk [odds ration, 3.2 (P=0.16; 95% confidence interval, 0.76-13.9) and 3.9 (P=0.09; 95% confidence interval, 0.93-16.3), respectively].
|
18842997 |
2008 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Based on the hypothesis that variants of the cSHMT C1420T together with methionine synthase (MS A2756G) and 5,10-methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) are associated with breast cancer, we performed a multigenic case-control study of the effects to breast cancer risk of four polymorphisms of folate-metabolizing genes against duration of estrogen exposure.
|
17896178 |
2008 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated case-control association of MTHFR C677T, A1298C, and MTR A2756G polymorphisms for cases strata-defined by promoter methylation status for each of three genes, E-cadherin, p16, and RAR-beta2 in breast cancer; in addition, we evaluated case-case comparisons of the likelihood of promoter methylation in relation to genotypes using a population-based case-control study conducted in Western New York State.
|
19240236 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated the association of polymorphisms in MTHFR (rs1801133 and rs1801131) and MTR (rs1805087) with breast cancer risk and their interaction with alcohol consumption in a case-control study--the Western New York Exposures and Breast Cancer study.
|
19706843 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Taken together, the results suggest that the MTR A2756G polymorphism may contribute to susceptibility to breast cancer among Europeans.
|
20111902 |
2010 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this case-control study, we investigated the association between MTHFR C677T and A1298C, TYMS 5'-UTR, MTR A2756G and cSHMT C1420T and also the folate carrier (RFC1 G80A) and breast cancer risk in a northeastern Brazilian population.
|
22134752 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study points out the importance of the interactions between the MTHFR C677T, MTHFR A1298C and MTR A2756G polymorphisms, and also highlights the relevance of the MTR A2756G polymorphism and age in breast cancer risk.
|
23155246 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, the findings suggest that MTR A2756G polymorphism is not associated with altered susceptibility to breast cancer, while the observed decreased risk in Caucasians, PB subgroup, and large studies and increased risk in small studies may be due to selection bias or other unknown factors.
|
23845785 |
2013 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We did not find a significant effect of the MTHFR A1298C and MTR A2756G on the risk of breast cancer.
|
25366783 |
2014 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This case-control study found that the MTHFR C677T and MTR A2756G polymorphisms are associated with risk of breast cancer, and folate, vitamin B6, and vitamin B12 intakes influence these associations.
|
25217320 |
2014 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of MTHFR C677T and MTR A2756G polymorphisms in thyroid and breast cancer development.
|
27173331 |
2016 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
SHMT C1420T mutations may reduce breast cancer susceptibility, whereas MTRR A66G and MS A2756G mutations may increase breast cancer susceptibility.
|
27347936 |
2016 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
MTR c.2756A>G polymorphism may confer protection for BC associated with iAs exposure.
|
28889078 |
2017 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, the present meta-analysis indicated that MTRR rs1801394, MTR rs1805087, and MTHFR rs1801133 polymorphisms could be used to identify individuals at high risk of developing BC.
|
31549463 |
2020 |